Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes Management
Diabetes Medication and Drugs
Incretin Mimetics
VICTOZA users
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="cugila" data-source="post: 118595" data-attributes="member: 15325"><p><strong>Re: VICTOZA - Taspoglutide</strong></p><p></p><p></p><p></p><p></p><p>We have known of this trial since 2008 when the Phase III Clinical Trials started. It will be some time before it ever gets the go ahead. As with all drugs everything takes time......here is a Press Release about the latest stage of progress.</p><p></p><p>Thursday 17th December 2009</p><p>Roche has announced the results of two T-emerge phase III trials of taspoglutide, a once-weekly glucagon-like peptide-1 therapy for patients with diabetes. It emerged from research by Ipsen.</p><p></p><p>T-emerge 5 tested subcutaneous weekly taspoglutide as an add-on to metformin in patients not responding to metformin and sulfonylurea. T-emerge 7 was a similar test for patients with high body-mass indices.</p><p></p><p>Roche reports that the treatment was generally well tolerated in both studies, the most frequently reported adverse reactions being nausea and vomiting.</p><p></p><p>Taspoglutide is similar to the natural hormone GLP-1, which has a key role in blood-sugar regulation. Substitutes that stimulate insulin and suppress glucagon are regarded as true innovations.</p><p></p><p>Copyright Press Association 2009</p><p></p><p>The data shows that taspoglutide is a promising once weekly treatment for patients with type 2 diabetes mellitus no longer controlled on oral antidiabetic medications," said lead author, Professor Michael Nauck, Head of the Diabeteszentrum Bad Lauterberg, Germany. "Like improved glucose control, drug-induced weight loss is particularly beneficial for this type of patient. We will wait to see the Phase III results with interest."</p><p></p><p>We certainly have no further data which states if it is any better than Byetta or Victoza......most drug companies always say it is better than x or y drug etc......I think I will wait and see.</p></blockquote><p></p>
[QUOTE="cugila, post: 118595, member: 15325"] [b]Re: VICTOZA - Taspoglutide[/b] We have known of this trial since 2008 when the Phase III Clinical Trials started. It will be some time before it ever gets the go ahead. As with all drugs everything takes time......here is a Press Release about the latest stage of progress. Thursday 17th December 2009 Roche has announced the results of two T-emerge phase III trials of taspoglutide, a once-weekly glucagon-like peptide-1 therapy for patients with diabetes. It emerged from research by Ipsen. T-emerge 5 tested subcutaneous weekly taspoglutide as an add-on to metformin in patients not responding to metformin and sulfonylurea. T-emerge 7 was a similar test for patients with high body-mass indices. Roche reports that the treatment was generally well tolerated in both studies, the most frequently reported adverse reactions being nausea and vomiting. Taspoglutide is similar to the natural hormone GLP-1, which has a key role in blood-sugar regulation. Substitutes that stimulate insulin and suppress glucagon are regarded as true innovations. Copyright Press Association 2009 The data shows that taspoglutide is a promising once weekly treatment for patients with type 2 diabetes mellitus no longer controlled on oral antidiabetic medications," said lead author, Professor Michael Nauck, Head of the Diabeteszentrum Bad Lauterberg, Germany. "Like improved glucose control, drug-induced weight loss is particularly beneficial for this type of patient. We will wait to see the Phase III results with interest." We certainly have no further data which states if it is any better than Byetta or Victoza......most drug companies always say it is better than x or y drug etc......I think I will wait and see. [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes Management
Diabetes Medication and Drugs
Incretin Mimetics
VICTOZA users
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…